| protein
| Cyclin A/CDK2 ( |
|
Rb and adenovirus E4 proteins ( |
|
DP1 ( |
|
CBP ( |
|
BRCA1 ( |
|
NF-kappaB ( |
|
DDB ( |
|
Necdin, NDN ( |
|
transformation/transcription domain-associated protein, TRRAP ( |
|
E2FBP1 ( |
|
Sp1 ( |
|
ubiquitin-protein ligase SCFSKP2 ( |
|
DNA (cytosine-5-)-methyltransferase 1, DNMT1 ( |
|
neural proliferation, differentiation and control 1, NPDC1 ( |
|
p553 ( |
|
CHK2 checkpoint homolog (S. pombe), CHEK2 ( |
|
p107 (RBL1, p130 (RBL2) binding |
|
inducing TP73 and indirectly TP53 |
|
TRAF2 (downregulation of TRAF2)inducing apoptosis |
|
inducing SIVA |
|
PHB |
|
RB1 and CEBP1 important in C/EBPepsilon-induced terminal granulocytic differentiation |
|
RHOBTB2 (novel direct target of E2F1 with roles in cell cycle and apoptosis) |
|
positive transcriptional regulator for CTNND1 |
|
poly (ADP-ribose) polymerase 1, PARP1 ( |
|
Activating signal cointegrator-2A, SC-2 ( |
|
HAT Tip60 ( |
|
ACTR ( |
|
PURA ( |
|
E2F-associated phosphoprotein, EAPP ( |
|
ASPP1 and ASPP2 ( |
|
p21 ( |
|
MDM2 ( |
|
NRP1 (positively regulates NRP1 during cerebral ischemia) |
|
DUSP2, binds to its consensus sequence in the promoter and transactivates the DUSP2 promoter |
|
host cell factor 1, HCF1( |
|
lymphoid enhancer-binding factor 1, LEF1 ( |
|
COPS2 (acts as a corepressor for E2F1 and is involved in cell cycle regulation) |
|
with E2F1 contribute to ATM-dependent phosphorylation of p53 and apoptosis in cells expressing E1A |
|
GSK3 beta ( |
|
microcephalin 1, MCPH1 ( |
|
CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes ECT2, RACGAP1, and KIF23 in S phase |
|
HCFC1 (E2F1 HCFC1-binding site can modulate both up and down the ability of E2F1 to induce apoptosis indicating that HCFC1 association with E2F1 is a regulator of E2F1-induced apoptosis) ( |
|
RRP1B, is an E2F1-specific transcriptional target (RRP1B is required for the expression of certain E2F1 proapoptotic target genes and the induction of apoptosis by DNA-damaging agents) |
|
is necessary, but not sufficient, to activate PCYT1A expression when this factor is over-expressed |
|
E2F1-CDKN1C interaction mediated by two E2F domains (a central E2F1 domain interacts directly with CDKN1C, whereas a C-terminal E2F1 domain interacts with CDKN1C via interaction with Rb) |
|
DP-4 ( |
|
negatively regulates IRF3 transcription through binding to the E2F consensus binding site) |
|
physically interacts with the HELLS promoter by binding to each of the two putative binding sites and transactivates the HELLS promoter |
|
negatively regulate Wnt/CTNNB activity in colorectal cancers |
|
activation of CTNNBIP1 by E2F1 is required for E2F1 to inhibit CTNNB activity |
|
BIRC2 dramatically increases the transcriptional activity of E2F1 on synthetic and CCNE promoters |
|
CDKN2A is a modulator of transcription and apoptosis through controlling the expression of two major transcription regulators, HNRNPD and E2F1 |
|
has an inhibitory role in TP53-mediated apoptosis |
|
KLF15 inhibits mesangial cell proliferation, possibly by regulating the expression of cell cycle regulation proteins through E2F1 |
|
E2F1 is a substrate for NEDD8 post-translational modification (NEDDylation results in decreased E2F1 stability, lower transcriptional activity and slower cell growth) |
|
RB1 protein selectively represses specific E2F1 target genes via a TAAC element in senescent cells |
|
RSLID1 is a direct target of E2F1 |
|
SENP8 promoted the interaction between E2F1 and its cofactor MCPH1, which is required for TP73 induction |
|
DOK1 is regulated mainly by the transcription factor E2F1 |
|
binds to the BCL2L11 promoter at multiple sites |
|
SRSF2 is a new transcriptional target of E2F1 and both proteins cooperate to induce apoptosis in non-small cell lung carcinoma |
|
NELL2 is a novel target gene of E2F1, which is a key regulator of cell proliferation |
|
UHRF2 directly interacts with E2F1, and is required for E2F1 induction of apoptosis and transcription of a number of important apoptotic regulators) |
|
E2F1/FOXO1/FOXO3 cooperation is a regulatory mechanism that places E2F1 apoptotic activity under the control of survival signaling |
|
direct downstream target gene of ELL (ELL enhanced E2F1 deacetylation via recruitment of HDAC1 |
|
TFDP3 is likely involved in prostate cancer cell survival by suppressing apoptosis induced by E2F1 |
|
RORA bound to the heptad repeat and marked box region of E2F1 and suppressed E2F1-regulated transcription in epithelial cells |
|
likely a regulatory role for KDM2A in breast cancer cell invasion and migration, through the regulation of E2F1 function |
|
role of E2F1 in the regulation of RRM2B expression in DNA damage response (DDR) |
|
E2F1 can promote colorectal cancer proliferation, migration, invasion and metastasis by regulating RRM2 transactivation |
|
UCHL5 expression is induced by E2F1, and its level rises in G1/S transition and S phase, suggesting a positive feedback loop between UCHL5 and E2F1 |
|
deubiquitylase PSMD14 stabilizes E2F1 protein through binding to and deubiquitylating E2F1, and hyperactivated PSMD14-E2F1 regulation may contribute to the development of liver cancer 6) |
|
STAU2 is likely an anti-apoptotic protein that could be involved in DNA replication and/or maintenance of genome integrity and its expression is regulated by E2F1 via the ATR signaling pathway |
|
FZR1 regulates E2F1 degradation in response to differentiation signals in keratinocytes |
|
NOVA2 integrated splicing decisions in order to regulate PPPARG and E2F1 activities |
|
mechanistically, SAPCD2 could directly bind to cytoplasmic E2F7 but not E2F1, alter the subcellular distribution of E2F7 and regulate E2F activity |
